RxDoctor Payments Data

Daniel Cabello, MD

Neurology · Clearwater, FLNPI 1730196965

Payments from drug & device makers

$90,213in general payments, 2019–2025

Across 1,541 payments — averaging $58.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$29K
  • Sunovion Pharmaceuticals Inc.$19K
  • Eisai Inc.$12K
  • UCB, Inc.$7K
  • AbbVie$4K
  • Jazz Pharmaceuticals Inc.$2K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$3,3254%
  • Speaking & faculty fees$38,84249%
  • Travel & lodging$7,0899%
  • Food & beverage$29,57737%
  • Education$3200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.114$29,415
Sunovion Pharmaceuticals Inc.62$19,429
Eisai Inc.76$12,485
UCB, Inc.190$7,406
AbbVie(2 entities)206$3,760
Jazz Pharmaceuticals Inc.77$1,933
Lundbeck LLC52$1,097
Pfizer69$1,084
Lilly USA, LLC47$946
Acadia Pharmaceuticals Inc44$856
Harmony Biosciences LLC36$846
Amgen43$718
Neurocrine Biosciences, Inc.37$679
Teva Pharmaceuticals USA, Inc.41$656
Otsuka America Pharmaceutical, Inc.34$647
Upsher-smith Laboratories LLC27$642
Livanova USA, Inc.7$590
Argenx US, Inc.22$581
Neurelis, Inc.25$472
Catalyst Pharmaceuticals, Inc.18$439
Scilex Pharmaceuticals Inc.18$392
Avanir Pharmaceuticals, Inc.23$340
Sumitomo Pharma America, Inc.18$331
Biohaven Pharmaceuticals, Inc.24$289
Novartis14$274
Biohaven Pharmaceutical Holding Company Ltd.18$257
Merz Pharmaceuticals, LLC10$239
Supernus Pharmaceuticals, Inc.21$228
Axsome Therapeutics, Inc.15$222
Amneal Pharmaceuticals LLC11$219
Neuropace, Inc.6$212
Greenwich Biosciences, Inc.12$180
Acorda Therapeutics, Inc7$175
Impel Pharmaceuticals Inc.9$173
Adamas Pharmaceuticals, Inc.9$149
Kyowa Kirin, Inc.7$149
Arbor Pharmaceuticals, Inc.8$148
GE HealthCare6$120
MDD US Operations, LLC5$99
Merck5$93
Almatica Pharma LLC5$91
Idorsia Pharmaceuticals US Inc6$89
Currax Pharmaceuticals LLC6$87
AstraZeneca(2 entities)5$87
Azurity Pharmaceuticals, Inc.4$82
Avion Pharmaceuticals4$73
Vanda Pharmaceuticals Inc.3$64
TG Therapeutics, Inc.2$55
Mallinckrodt Hospital Products Inc.2$53
Impel Pharmaceuticals LLC2$52
Takeda Pharmaceuticals U.S.A., Inc.2$52
Nevro Corp.2$51
Tonix Medicines, Inc.3$48
Aquestive Therapeutics, Inc.2$42
Portola Pharmaceuticals, LLC2$40
GRT US Holding, Inc.2$37
Collegium Pharmaceutical, Inc.2$32
Genentech USA, Inc.2$29
Johnson & Johnson(2 entities)2$27
Zyla Life Sciences, Inc.2$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,213 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$234,165
Medicare patients
390
Services billed
1,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)109$447,724
FinteplaFenfluramine Hcl19$344,162
XcopriCenobamate178$313,663
AptiomEslicarbazepine Acetate123$206,239
FycompaPerampanel105$180,306
NayzilamMidazolam49$127,173
Lamictal XrLamotrigine26$119,261
BriviactBrivaracetam59$99,656
OnfiClobazam23$83,053
Lamotrigine ErLamotrigine170$51,424
QuliptaAtogepant43$50,530
Lacosamide263$45,962
UbrelvyUbrogepant23$38,549
Levetiracetam ErLevetiracetam288$32,262
SunosiSolriamfetol Hcl27$30,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Fintepla, Nayzilam, Briviact$7,406$570,990127 claims
SK Life Science, Inc.Xcopri$29,415$313,663178 claims
Sunovion Pharmaceuticals Inc.Aptiom$19,429$206,239123 claims
Eisai Inc.Fycompa, Dayvigo$12,485$188,215122 claims
AbbVieQulipta, Ubrelvy$3,760$89,07966 claims
Lundbeck LLCOnfi$1,097$83,05323 claims
PfizerNurtec Odt, Dilantin$1,084$32,82654 claims
Axsome Therapeutics, Inc.Sunosi$222$30,65527 claims
Johnson & JohnsonInvega Sustenna$27$22,75014 claims
MerckBelsomra$93$20,25429 claims
Azurity Pharmaceuticals, Inc.Zonisade$82$20,07413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →